These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 29069037)

  • 1. Dopamine versus norepinephrine in the treatment of cardiogenic shock: A PRISMA-compliant meta-analysis.
    Rui Q; Jiang Y; Chen M; Zhang N; Yang H; Zhou Y
    Medicine (Baltimore); 2017 Oct; 96(43):e8402. PubMed ID: 29069037
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome.
    Schumann J; Henrich EC; Strobl H; Prondzinsky R; Weiche S; Thiele H; Werdan K; Frantz S; Unverzagt S
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009669. PubMed ID: 29376560
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Saving the patient with post-ACS cardiogenic shock.
    Mwesige J; Uriel N; Singh M; Prasad H; Stapleton D; Kaluski E
    Minerva Cardioangiol; 2013 Jun; 61(3):281-93. PubMed ID: 23681131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epinephrine Versus Norepinephrine for Cardiogenic Shock After Acute Myocardial Infarction.
    Levy B; Clere-Jehl R; Legras A; Morichau-Beauchant T; Leone M; Frederique G; Quenot JP; Kimmoun A; Cariou A; Lassus J; Harjola VP; Meziani F; Louis G; Rossignol P; Duarte K; Girerd N; Mebazaa A; Vignon P;
    J Am Coll Cardiol; 2018 Jul; 72(2):173-182. PubMed ID: 29976291
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of dopamine and norepinephrine in shock.
    Lee J
    N Engl J Med; 2010 Jun; 362(24):2328-9; author reply 2330-1. PubMed ID: 20560159
    [No Abstract]   [Full Text] [Related]  

  • 6. [Effectiveness of norepinephrine versus dopamine for septic shock: a meta analysis].
    Zhou FH; Song Q
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2013 Aug; 25(8):449-54. PubMed ID: 24021037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dopamine versus norepinephrine in the treatment of shock.
    Nathan Coxford R; Lang E; Dowling S
    CJEM; 2011 Nov; 13(6):395-7. PubMed ID: 22436478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dopamine versus norepinephrine as the first-line vasopressor in the treatment of cardiogenic shock.
    Na SJ; Yang JH; Ko RE; Chung CR; Cho YH; Choi KH; Kim D; Park TK; Lee JM; Song YB; Choi JO; Hahn JY; Choi SH; Gwon HC
    PLoS One; 2022; 17(11):e0277087. PubMed ID: 36327286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Norepinephrine or dopamine for septic shock: systematic review of randomized clinical trials.
    Vasu TS; Cavallazzi R; Hirani A; Kaplan G; Leiby B; Marik PE
    J Intensive Care Med; 2012; 27(3):172-8. PubMed ID: 21436167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dopamine versus norepinephrine in the treatment of septic shock: a meta-analysis*.
    De Backer D; Aldecoa C; Njimi H; Vincent JL
    Crit Care Med; 2012 Mar; 40(3):725-30. PubMed ID: 22036860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of survival in unselected patients with acute myocardial infarction requiring continuous catecholamine support.
    Schreiber W; Herkner H; Koreny M; Bur A; Hirschl MM; Glogar D; Huber K; Laggner AN
    Resuscitation; 2002 Dec; 55(3):269-76. PubMed ID: 12458064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of dopamine and norepinephrine in the treatment of shock.
    De Backer D; Biston P; Devriendt J; Madl C; Chochrad D; Aldecoa C; Brasseur A; Defrance P; Gottignies P; Vincent JL;
    N Engl J Med; 2010 Mar; 362(9):779-89. PubMed ID: 20200382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of dopamine and norepinephrine in shock.
    De Santis V; Nencini C; Tritapepe L
    N Engl J Med; 2010 Jun; 362(24):2329; author reply 2330-1. PubMed ID: 20560160
    [No Abstract]   [Full Text] [Related]  

  • 14. Inotropic agents in the treatment of cardiogenic shock.
    Bourdarias JP; Dubourg O; Gueret P; Ferrier A; Bardet J
    Pharmacol Ther; 1983; 22(1):53-79. PubMed ID: 6361798
    [No Abstract]   [Full Text] [Related]  

  • 15. Network Meta-Analysis of the Safety of Drug Therapy for Cardiogenic Shock.
    Liao X; Qian L; Zhang S; Chen X; Lei J
    J Healthc Eng; 2020; 2020():8862256. PubMed ID: 32802302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inotropic agents and vasodilator strategies for acute myocardial infarction complicated by cardiogenic shock or low cardiac output syndrome.
    Unverzagt S; Wachsmuth L; Hirsch K; Thiele H; Buerke M; Haerting J; Werdan K; Prondzinsky R
    Cochrane Database Syst Rev; 2014 Jan; (1):CD009669. PubMed ID: 24385385
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of cardiogenic shock: Results from a survey in France and Belgium].
    Champion S; Deye N
    Ann Cardiol Angeiol (Paris); 2017 Apr; 66(2):59-65. PubMed ID: 27836099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inotropic therapy for cardiac low output syndrome: comparison of hemodynamic effects of dopamine/dobutamine versus dopamine/dopexamine.
    El Mokhtari NE; Arlt A; Meissner A; Lins M
    Eur J Med Res; 2007 Nov; 12(11):563-7. PubMed ID: 18024265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of dopamine and norepinephrine in shock.
    Romero CM
    N Engl J Med; 2010 Jun; 362(24):2328; author reply 2330-1. PubMed ID: 20554990
    [No Abstract]   [Full Text] [Related]  

  • 20. Inotropes and vasopressors use in cardiogenic shock: when, which and how much?
    Levy B; Buzon J; Kimmoun A
    Curr Opin Crit Care; 2019 Aug; 25(4):384-390. PubMed ID: 31166204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.